J&J’s Tremfya shows significant improvements for post-TNFi psoriatic arthritis patients
Johnson & Johnson’s (J&J) interleukin-23 (IL-23) Tremfya has demonstrated positive results in post-tumour necrosis factor (TNF) inhibitor-treated psoriatic arthritis (PsA) patients.
The COSMOS Phase IIIb study evaluated the safety and efficacy of Tremfya (guselkumab) in 285 patients with active PsA and who had demonstrated an inadequate response or intolerance to tumour necrosis factor inhibition (TNFi)
In this study, significantly higher proportions of Tremfya-treated patients showed both joint symptom improvement and complete skin clearance versus placebo at week 24 in the difficult-to-treat true TNFi patient population.
The results showed that 44.4% of patients who received Tremfya versus 19.8% of patients who received placebo achieved at least 20% improvement in the American College of Rheumatology criteria (ARC20) at week 24.
Read more: https://www.pharmatimes.com/news/j_and_js_tremfya_shows_significant_improvements_for_post-tnfi_psoriatic_arthritis_patients_1371148
The COSMOS Phase IIIb study evaluated the safety and efficacy of Tremfya (guselkumab) in 285 patients with active PsA and who had demonstrated an inadequate response or intolerance to tumour necrosis factor inhibition (TNFi)
In this study, significantly higher proportions of Tremfya-treated patients showed both joint symptom improvement and complete skin clearance versus placebo at week 24 in the difficult-to-treat true TNFi patient population.
The results showed that 44.4% of patients who received Tremfya versus 19.8% of patients who received placebo achieved at least 20% improvement in the American College of Rheumatology criteria (ARC20) at week 24.
Read more: https://www.pharmatimes.com/news/j_and_js_tremfya_shows_significant_improvements_for_post-tnfi_psoriatic_arthritis_patients_1371148
